ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Pacira Pharmaceuticals, Inc." (PCRX) Report Updated: Apr 14, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Pacira Pharmaceuticals, Inc." (PCRX)

Rating: Strong Buy Volatility: Moderate
Total Grade: A Industry: Pharmaceuticals
Competitors: ACT, FLML, HZNP, BPTH

Stock Analysis

Rating: Monthly View

A
B
C
D
F
April May June July August September October November December January February March

Rating: Weekly View

This Week: A down no change
Last Week: A same no change
Two Weeks Ago: A up no change
service keys

"Pacira Pharmaceuticals, Inc."© quotemedia

Company Profile

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers. The company develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. Its product portfolio includes EXPAREL, a long-acting non-opioid postsurgical analgesic for postsurgical pain management; DepoCyt for the treatment of lymphomatous meningitis, a cancer of the immune system; DepoDur for controlling post operative pain; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate that is in preclinical trials for the treatment of rheumatoid arthritis oncology. Pacira Pharmaceuticals, Inc. was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Recent News: "Pacira Pharmaceuticals, Inc."